×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Cepharanthine (千金藤素) - Investigational Therapy for Parkinson
clinical
1,414 words
KG: Cepharanthine (千金藤素) - Investigational Therapy for Parkinson's Disease
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
topic:parkinsons-disease
topic:natural-product
topic:drug-repurposing
topic:alpha-synuclein
Contents
Cepharanthine (千金藤素) - Investigational Therapy for Parkinson's Disease
Knowledge Graph
Related Hypotheses (30)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
APOE-Dependent Autophagy Restoration
Score: 0.61
PARP1 Inhibition Therapy
Score: 0.58
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55
Senescent Cell Mitochondrial DNA Release
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51
Ganglioside Rebalancing Therapy
Score: 0.50
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Lysosomal Enzyme Trafficking Correction
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.48
Complement C1q Mimetic Decoy Therapy
Score: 0.48
TFAM overexpression creates mitochondrial donor-recipient gr
Score: 0.47
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.47
Arginine Methylation Enhancement Therapy
Score: 0.46
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.45
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.45
Lysosomal Membrane Repair Enhancement
Score: 0.45
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.44
Mitochondrial Transfer Pathway Enhancement
Score: 0.44
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.43
R-Loop Resolution Enhancement Therapy
Score: 0.43
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.41
Glial Glycocalyx Remodeling Therapy
Score: 0.41
Show 25 more
Related Analyses (27)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Show 22 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40
Show 25 more
Knowledge Graph (1 edges)
Cepharanthine (千金藤素) - Investigational Therapy for Parkinson's Disease
references
TH